Chiglitazar

Drug Profile

Chiglitazar

Alternative Names: CS-038

Latest Information Update: 15 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chipscreen Biosciences
  • Class Antihyperglycaemics; Carbazoles; Propionic acids; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus
  • Preclinical Parkinson's disease

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 15 Sep 2016 Chiglitazar is still in phase III trials for Type-2 diabetes mellitus in China (PO)
  • 01 Jun 2014 Chipscreen Biosciences initiates enrolment in the phase III CMAS trial for Type-2 diabetes mellitus in China (NCT02173457)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top